证券时报·数据宝统计，截至今日上午10:29，上证综指3636.69点，收于半年线之上，涨跌幅-0.08%，A 股总成交额为8029.00亿元。到目前为止，今日有38只A股价格突破了半年线，其中乖离率较大的个股有 美好医疗、福石控股、金丹科技等，乖离率分别为8.17%、3.74%、3.27%；碧水源、京山轻机、华能水 电等个股乖离率较小，刚刚站上半年线。 8月8日突破半年线个股乖离率排名 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 301363 | 美好医 | 8.08 | 9.06 | 18.67 | 20.20 | 8.17 | | | 疗 | | | | | | | 300071 | 福石控 股 | 4.72 | 10.77 | 5.35 | 5.55 | 3.74 | | 300829 | 金丹科 技 | 4.28 | 6.77 | 17.94 | 18.53 | 3.27 | | ...

医疗器械 ETF（562600）为投资者提供一键把握医疗器械行业成长机遇的便捷工具。该ETF追踪的中证 全指医疗器械指数，精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上 市公司证券作为样本。按wind脑机接口指数测算，截至2025年8月6日指数含脑机接口权重21.9%，从行 业结构看，该指数医疗器械行业占比高达 89.08%，集中度突出，能精准捕捉医疗器械领域的发展红 利。感兴趣的投资者可以持续关注。 （文章来源：每日经济新闻） 提出到2027年、2030年两步走发展目标，明确五大重点任务，细化17项具体举措，进一步推动脑机接口 产业高质量发展。这一重磅文件的出台，为我国脑机接口产业的未来发展描绘了清晰的蓝图，有望在全 球科技竞争中抢占先机，培育出具有国际竞争力的未来产业新赛道。 受此影响，医疗器械板块持续活跃，医疗器械ETF短暂调整后直线拉升，发稿时涨超1%。持仓股票赛 诺医疗20厘米涨停，利德曼、麦澜德、尚荣医疗、美好医疗涨幅居前。 消息面，工业和信息化部、国家发展改革委等7 部门发布关于推动脑机接口产业创新发展的实施意见。 ...

证券日报网讯美好医疗（301363）8月4日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东总数为13185户。 ...

从8月4日公开信息显示，美好医疗截至2025年7月31日公司股东户数为1.32万户，较上期（2025年7月18日）增加87户，增幅 为0.66%，变化不大。 从数据对比来看，美好医疗户均持股数从上期4.34万股下降至本期4.31万股，户均持股市值从上期80.70万元下降至本期79.69 万元。上述区间，美好医疗股价累计下跌0.96%。 截至发稿，美好医疗报18.61元，下跌0.16%，市值105.87亿元。 最新5个统计日期，美好医疗股东户数变动如下： 统计日期股东户数户均持股数（万股）户均持股市值（万元） 2025/07/31131854.3179.692025/07/18130984.3480.702025/06/30124874.5680.362025/06/10123024.6281.622025/05/30112653.6185.34 来源：金融界 ...

融券方面，当日融券卖出0.11万股，净卖出0.10万股。 来源：金融界 7月31日，沪深两融数据显示，美好医疗获融资买入额0.11亿元，居两市第2623位，当日融资偿还额0.11 亿元，净买入6.70万元。 最近三个交易日，29日-31日，美好医疗分别获融资买入0.14亿元、0.14亿元、0.11亿元。 ...

7月30日，沪深两融数据显示，美好医疗获融资买入额0.14亿元，居两市第2417位，当日融资偿还额0.13 亿元，净买入55.72万元。 最近三个交易日，28日-30日，美好医疗分别获融资买入0.05亿元、0.14亿元、0.14亿元。 融券方面，当日融券卖出0.00万股，净买入0.97万股。 来源：金融界 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Meihao Medical (301363), indicating a slight decline in stock price and a mixed financial outlook for the first quarter of 2025 [1][3] - As of July 29, 2025, Meihao Medical's stock closed at 19.0 yuan, down 0.89%, with a turnover rate of 4.85% and a trading volume of 75,700 hands, amounting to a transaction value of 143 million yuan [1] - The company experienced a net outflow of main funds amounting to 13.99 million yuan, representing 9.78% of the transaction value, with significant outflows from large and medium orders [1] Group 2 - For the first quarter of 2025, Meihao Medical reported total operating revenue of 296 million yuan, reflecting a year-on-year growth of 5.05%, while net profit attributable to shareholders decreased by 10.62% to 51.88 million yuan [1] - The company's financial ratios indicate a current ratio of 5.964, a quick ratio of 5.060, and a debt-to-asset ratio of 12.08%, suggesting a strong liquidity position [1] - Meihao Medical, established in 2010 and based in Shenzhen, has a registered capital of 406.66 million yuan and a paid-in capital of 321.16 million yuan [1][2]

Group 1 - The medical device industry experienced a decline of 0.17% on July 29, with a net outflow of 351 million yuan in main funds, where 55 stocks rose and 43 fell [1] - The companies with the highest net outflow of main funds included Yirui Technology (14.03 million yuan), Meihao Medical (13.99 million yuan), Aohua Endoscopy (13.90 million yuan), Kangzhong Medical (13.42 million yuan), and Microelectrophysiology (12.50 million yuan) [1] Group 2 - Notable stock performance included BGI Genomics with a price of 53.69 and a rise of 3.17%, attracting a net inflow of 745.64 million yuan, representing 10.25% of the main fund [2] - Other companies with significant movements included Nanwei Medical, which fell by 1.27% to 84.08, with a net inflow of 535.99 million yuan (11.35%); Sanofi Biological, which dropped by 6.62% to 21.44, with a net inflow of 507.66 million yuan (6.33%); and Haooubo, which rose by 2.86% to 124.82, with a net inflow of 426.62 million yuan (18.96%) [2]

Summary of Key Points Core Viewpoint The company, Shenzhen Meihua Chuangyi Medical Technology Co., Ltd., has approved an increase in the guarantee limits for its subsidiaries to support their operational and business development needs, with a total guarantee amount not exceeding RMB 1 billion. Group 1: Guarantee Adjustments - The company and its subsidiaries have approved a total guarantee amount of up to RMB 1 billion, which includes guarantees for Huizhou Meihua, Malaysia Meihua, and Malaysia Miman [1][2][9] - The specific guarantees include RMB 300 million for Huizhou Meihua, RMB 200 million for Malaysia Meihua, and RMB 500 million for Malaysia Miman [1][2] Group 2: Subsidiary Information - Huizhou Meihua was established on April 12, 2018, with a registered capital of RMB 900 million, focusing on medical device production and sales [3][5] - Hong Kong Meihua, established on March 20, 2015, has a registered capital of HKD 80 million and is a wholly-owned subsidiary [5] - Malaysia Meihua, established in December 2015, has a registered capital of RM 41.16 million and is involved in the manufacturing and sales of medical devices [5][6] - Malaysia Miman, established on May 30, 2023, has a registered capital of RM 23.325 million and focuses on manufacturing plastic products [7] Group 3: Financial Indicators - As of March 31, 2025, Huizhou Meihua reported total assets of RMB 150.12 million and net assets of RMB 128.09 million [5] - Hong Kong Meihua reported total assets of RMB 62.03 million and net assets of RMB 32.77 million [5] - Malaysia Meihua reported total assets of RM 50.10 million and net assets of RM 35.88 million [6] - Malaysia Miman reported total assets of RM 29.21 million and net assets of RM 16.49 million [8] Group 4: Guarantee Agreement Details - The guarantees are expected and the related agreements have not yet been signed, with terms to be negotiated with creditors [8] - The board believes that these guarantees will not adversely affect the company, as it maintains control over the subsidiaries [8][9]

Core Points - The company announced an adjustment to the expected guarantee amount for itself and its subsidiaries, totaling up to 1.8 billion RMB, which represents 51.73% of the audited net assets as of the end of 2024 [1][2] - The adjustment includes additional subsidiaries such as Hong Kong Meihao, Cayman Meihao, and Singapore Meihao, expanding the scope of the guarantees [1] - As of June 30, 2025, the outstanding guarantee balance is 41 million RMB, accounting for 1.18% of the audited net assets as of the end of 2024 [1] Summary by Sections Guarantee Amount Adjustment - The company held a meeting on July 24 to review and approve the adjustment of the expected guarantee amount, which now totals 1.8 billion RMB [1] - The guarantees include amounts for Huizhou Meihao (up to 300 million RMB), Malaysia Meihao (up to 200 million RMB), and Malaysia Miman (up to 500 million RMB) [1] Subsidiaries Involved - The adjustment includes guarantees for wholly-owned subsidiaries such as Hong Kong Meihao, Cayman Meihao, and Singapore Meihao, among others [1] - The announcement provided details on the subsidiaries, including establishment dates, registered capital, and recent financial data [1] Risk Management - The board believes that the guarantees are necessary to meet the funding needs of the subsidiaries for their production and business development [2] - The company has not provided guarantees for companies outside the consolidated financial statements and has no overdue external guarantees [2]